A novel mechanism of ACE inhibition–associated enhanced platelet reactivity: disproof of the ARB-MI paradox?

[1]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[2]  S. Bangalore,et al.  Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? , 2018, Journal of the American College of Cardiology.

[3]  T. Hohlfeld,et al.  Analgesic medication with dipyrone in patients with coronary artery disease: Relation to MACCE. , 2017, International journal of cardiology.

[4]  S. Bangalore,et al.  Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction. , 2017, Circulation.

[5]  T. Hohlfeld,et al.  Dipyrone comedication in aspirin treated stroke patients impairs outcome. , 2016, Vascular pharmacology.

[6]  N. Mackman,et al.  Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation , 2016, Cardiology.

[7]  M. Kelm,et al.  Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure , 2016, Platelets.

[8]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[9]  T. Hohlfeld,et al.  Antiplatelet effects of aspirin in chronic kidney disease patients , 2016, Journal of thrombosis and haemostasis : JTH.

[10]  T. Rassaf,et al.  Platelet reactivity in MitraClip patients. , 2016, Vascular pharmacology.

[11]  K. Schrör,et al.  Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects , 2015, Thrombosis and Haemostasis.

[12]  M. Kelm,et al.  High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. , 2015, European journal of pharmacology.

[13]  B. Jensen,et al.  Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. , 2014, Heart failure clinics.

[14]  R. Pawlinski,et al.  Tissue factor, protease activated receptors and pathologic heart remodelling , 2014, Thrombosis and Haemostasis.

[15]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[16]  E. Boersma,et al.  Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients , 2012, European heart journal.

[17]  G. Mancia,et al.  Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis , 2008, Journal of hypertension.

[18]  W Scott Beattie,et al.  Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[19]  J. Rosing,et al.  Development of a calibrated automated thrombography based thrombin generation test in mouse plasma , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  A. Bomback,et al.  The incidence and implications of aldosterone breakthrough , 2007, Nature Clinical Practice Nephrology.

[21]  A. Hall,et al.  Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox , 2006, Circulation.

[22]  I. Piña.  Valsartan in acute myocardial infarction trial. , 2004, Current cardiology reports.

[23]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[24]  S. Béguin,et al.  The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability , 2002, Pathophysiology of Haemostasis and Thrombosis.

[25]  R. Jennrich,et al.  Systolic blood pressure and mortality , 2000, The Lancet.

[26]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[27]  W. Kannel,et al.  VASCULAR DISEASE OF THE BRAIN--EPIDEMIOLOGIC ASPECTS: THE FARMINGHAM STUDY. , 1965, American journal of public health and the nation's health.

[28]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.

[29]  T. Dawber,et al.  Coronary heart disease in the Framingham study. , 1957, American journal of public health and the nation's health.

[30]  T. Dawber,et al.  II. Coronary Heart Disease in the Framingham Study , 1957 .

[31]  R. Schmieder,et al.  Guidelines for management of arterial hypertension , 2007 .